JURA Bio, Inc. is involved in generative machine learning applied to laboratory settings, specifically in protein and biologic sequence design. The company has developed a manufacturing-aware generative model architecture to reduce the cost of designing new proteins significantly.

JURA Bio, Inc.

JURA Bio, Inc. | 1,941 followers on LinkedIn. Building the future of cell-based therapies. | CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive.

Member Board of Directors @ JURA Bio, Inc. | Biotech Strategy Leader

Michelle Berg

Senior VP of R&D | Immunotherapy, Biologics Discovery

Cameron Gardner

Director of Machine Learning at JURA Bio. Probabilistic machine learning | immunology | molecular biology

Mattia Gollub

Postdoc with David Blei // ML at JURA Bio

Eli Weinstein

Tomorrow, Election Day, Eli Weinstein will present our work on *physically sampling* generative models of proteins by the quadrillion. #MoML2024 in Cambridge, MA: today is the last day to register! JURA Bio, Inc.

Elizabeth Wood

So pleased our work on #VariationalSynthesis was selected as one of the top 4 papers at MIT Jameel Clinic - AI & Health 's 5th Molecular Machine Learning Conference, #MoML2024 . Eli Weinstein will be giving a short talk in person if you'd like to learn more live. Early bird registration is already sold out, but you can get regular tickets or onto the waitlist at https://moml.mit.edu . And you can always reach out to us if you have to miss the in-person event but would still like to learn more about manufacturing-aware generative protein models. JURA Bio, Inc.

You can register now for free at https://lnkd.in/eeY6BkDC to listen to JURA Bio CEO Elizabeth Wood speak to the possibilities of foundation models in biology. She puts #variationalsynthesis as a tool for building incomparably large data sets for training these models into context.

CAIRE represents an incredible effort by JURA's head of machine learning research Eli Weinstein and David Blei (Columbia), as well as Elizabeth Wood to bring insights into clinical efficacy as far upstream as possible into the therapeutic design process. Pleased to release it to today and we encourage you to check out the blog post: https://lnkd.in/e7A3tyWr

Loved this closer look that Will Connell took into #VariationalSynthesis . I encourage you to give a read -- and in general, check out his substack, which I've enjoyed catchup up on: Behind BioML https://lnkd.in/ecTKavuf JURA Bio, Inc.

For those of you who enjoy learning through audio, please check out the new Deep Dive podcast into Variational Synthesis made in collaboration with Google's NotebookLM.

🧬 Direct synthesis of trillions of AI-designed protein candidates! It's a great feeling to share our results designing and building peta-scale libraries of antibodies, antigens and polymerases. High five to everyone involved at JURA Bio, Inc. , and in particular Eli Weinstein , Andrei Slabodkin and our CEO Elizabeth Wood , such a wonderful team to work with!

We invite you to read about our newest technology release at https://lnkd.in/eM7GbgWV . We've brought the cost of taking machine learning designed proteins off the computer into the real-world by a trillion-fold. #VariationalSynthesis #BioAI

We're excited to join the conversation at LSX World Congress USA tomorrow in Boston! Catch our CEO, Elizabeth Wood , on Day 1 from 1:40 to 2:30 PM EDT as she shares insights on "What trends in oncology and partnering are shaping the future of cancer treatment and where are the opportunities for innovation" with Alex Philippidis , Senior Business editor at Genetic Engineering & Biotechnology News , as moderator. This session will dive deep into the key areas that AI been reshaping — or has begun to reshape — cancer drug development. 🗓️ Explore more and check out the full agenda at www.lsxleaders.com/USA . #LSXUSA #Healthtech #Biotechnology #AI #MachineLearning #Oncology

Excited to be traveling out to Scotts Valley, California next week to speak at the Nucleate #AlumniSummit . I've always been such a big fan of this student-led organization: its community, and the environment for success that everyone at Nucleate has been building is really special; and it's a privilege to get to continue to support it as I can. Also excited to share a little of what JURA Bio, Inc. has been up to. With a couple of big preprints coming out in a few weeks -- one on our manufacturing aware AI-model architectures allowing us to build quadrillion-dollar protein libraries in the real world -- and another on our causal methods for mining observational experiments for indications of clinical safety and efficacy -- I hope it's an opportunity to give a glimpse of the future that AI-led-bio can achieve. If you're planning to be there, please give a 👋 https://lnkd.in/eSPkZepk

JURA

BIO:JURA

JURA Bio, Inc.